![]() |
市場調查報告書
商品編碼
2032828
血液氣體和電解質分析儀市場報告:按產品類型、測量方法、最終用戶和地區分類(2026-2034 年)Blood Gas and Electrolyte Analyzer Market Report by Product Type (Analyzers, Consumables), Modality (Benchtop, Portable), End User (Hospitals, Clinics, Ambulatory Surgical Centers, and Others), and Region 2026-2034 |
||||||
2025年,全球血氣和電解質分析儀市場規模達24億美元。展望未來,IMARC Group預測,到2034年,該市場規模將達到38億美元,2026年至2034年的複合年成長率為5.31%。推動市場成長的因素包括心血管疾病、癌症和糖尿病等各種慢性疾病發生率的上升,儀器小型化和精度提高等先進技術的應用,以及即時檢測(POC)服務的日益普及。
血氣電解質分析儀是一種用於測量全血樣本中各種參數的醫療設備,包括血氣(二氧化碳和氧氣的分壓)、pH值、電解質和代謝物。它們廣泛用於檢測代謝紊亂和評估腎臟及心臟功能。此外,它們還有助於評估血液中異常的電解質水平、氧氣和二氧化碳交換水平以及患者的酸鹼平衡。它們還可以幫助識別糖尿病、血管出血和藥物攝取。近年來,由於其操作簡便、經濟高效、準確可靠且結果快速,血氣電解質分析儀在臨床診斷檢查室和加護病房中得到了廣泛應用。
血氣和電解質分析儀能夠簡化工作流程、最大限度地減少錯誤、降低維護成本並快速提供準確結果。因此,加護病房(ICU)、手術室和急診科患者數量的不斷增加是市場成長的主要驅動力。此外,糖尿病和心血管疾病等慢性病的流行,以及易患這些疾病的老年人口的成長,也推動了產品需求。同時,對高通量、整合、自動化系統的需求也顯著成長。此外,血液氣體和電解質分析儀與實驗室資訊系統 (LIS) 和電子健康記錄(EMR) 的日益整合,能夠簡化工作流程並有效監測患者健康,這也推動了市場成長。此外,多家領先製造商正大力投資開發具有方便用戶使用功能和極低維護需求的攜帶式血氣和電解質分析儀。其他因素,例如向即時檢測 (POCT)的偏好、醫療產業的進步、技術進步、產品創新以及廣泛的研發活動,也為良好的市場前景做出了貢獻。
本報告分析了各細分市場的關鍵趨勢,並對2026年至2034年全球、區域和國家的市場進行了預測。報告根據產品類型、模式和最終用戶對市場進行了分類。
報告中還檢視了該行業的競爭格局,重點介紹了雅培實驗室、Darko Diagnostics、Elva Group(Transatia Biomedicals)、Medica Corporation、Nova Biomedical Corporation、OPTI Medical Systems(IDEXX Laboratories)、Radiometer Medical(Danaher 檢驗)、Roche Holding AG、Siemens SA. 和 WerfenLife 等主要公司。
The global blood gas and electrolyte analyzer market size reached USD 2.4 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 3.8 Billion by 2034, exhibiting a growth rate (CAGR) of 5.31% during 2026-2034. The growing occurrence of various chronic illnesses like cardiovascular complications, cancer, and diabetes, increasing integration of advanced technologies to decrease the size of devices and enhance accuracy, and rising adoption of point-of-care (POC) testing services are some of the factors impelling the growth of the market.
Blood gas and electrolyte analyzers refer to medical devices used to measure various parameters, including blood gas (partial pressure of carbon dioxide and oxygen), pH, electrolytes, and metabolites, in a whole blood sample. They are widely utilized for the detection of metabolic imbalances and the measurement of renal and cardiac functions. They also help determine abnormal electrolyte levels in the blood, levels of oxygen or carbon dioxide exchange, and the acid-base balance of the patient. Moreover, they assist in identifying diabetes, blood vessel hemorrhage, and drug consumption. In recent years, blood gas and electrolyte analyzers have gained immense popularity across clinical diagnostic labs and critical care units due to their ease of use, cost-effectiveness, accuracy, and fast results.
Blood gas and electrolyte analyzers can streamline work processes, minimize errors, require minimum maintenance, and provide accurate results quickly. As a result, the increasing number of patients in intensive care units (ICUs), operating rooms, and emergency departments represent the primary factor driving the market growth. Besides this, the widespread prevalence of chronic diseases, such as diabetes and cardiovascular disorders, and the growing geriatric population that is more susceptible to developing these medical ailments are augmenting the product demand. Additionally, there has been a significant increase in the demand for high throughput, integrated, and automated systems. Along with this, the rising integration of blood gas and electrolyte analyzers with laboratory information systems and electronic medical records to streamline the workflow and enable effective monitoring of patient health is catalyzing the market growth. Furthermore, several leading players are making heavy investments for the development of portable blood gas and electrolyte analyzers with easy-to-use and handle features and minimum maintenance requirements. Other factors, including the shifting preferences toward point-of-care testing (POCT), developments in the healthcare industry, technological advancements, product innovations, and extensive research and development (R&D) activities, are also creating a favorable market outlook.
This report provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2026-2034. The report categorizes the market based on product type, modality, and end user.
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories Inc., Dalko Diagnostics, Erba Group (Transasia Bio-Medicals Ltd.), Medica Corporation, Nova Biomedical Corporation, OPTI Medical Systems Inc. (IDEXX Laboratories), Radiometer Medical ApS (Danaher Corporation), Roche Holding AG, Siemens AG, and WerfenLife S.A.